Currently, the application of PD-1/PD-L1 blockades combined with novel targeted regimens in the treatment of breast cancer is in its infancy, and the specific mechanisms underlying synergistic or antagonistic effects need further investigation. The gene discussed is CD274; the disease is breast carcinoma.